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Down-regulation of urinary AQP2 and unaffected response to
hypertonic saline after 24 hours of fasting in humans
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Down-regulation of urinary AQP2 and unaffected response to
hypertonic saline after 24 hours of fasting in humans.
Background. In rats, 24 hours of fasting impairs urinary con-
centrating ability by down-regulation of aquaporin-2 (AQP2).
We tested the hypothesis that 24 hours of fasting in humans re-
duces the capability to form AQP2 and impairs the antidiuretic
response to hypertonic saline infusion.
Methods. In a crossover study of 14 healthy subjects, the effect
of 24 hours of fasting was compared to a nonfasting control
experiment on urinary excretion of AQP2 (u-AQP2), free water
clearance (CH2O), plasma arginine vasopressin (AVP), urinary
cyclic AMP (u-cAMP), and natriuretic peptides. The following
response to 3% sodium infusion was measured using the same
effect variables. U-AQP2, AVP, and u-cAMP were determined
by radioimmunoassays.
Results. Fasting during 24 hours reduced u-AQP2 (14%), in-
creased AVP (30%) despite a reduction in serum osmolality
(P < 0.05), and depleted volume. CH2O and urine volume were
not reduced, thus relatively increased after fasting. u-cAMP was
not significantly different between the two procedures. Three
percent saline resulted in the same relative increases in AVP,
serum osmolality, u-AQP2, and u-cAMP and decreases in CH2O
and urine volume independently of fasting. The reduced u-
AQP2 and increased AVP after fasting were maintained during
and after saline infusion.
Conclusion. Twenty-four hours of fasting decreased u-AQP2
and reduced urine osmolality likely as a result of decreased
sensitivity of collecting duct cells to AVP. Fasting-related insen-
sitivity of collecting duct cells to AVP was restored by 3% saline
infusion. Finallly, after saline infusion, other factors such as the
increased plasma atrial natriuretic peptide (p-ANP) levels could
contribute to the u-AQP2 regulation.
The plasma arginine vasopressin (AVP)-sensitive wa-
ter channel aquaporin-2 (AQP2) mediates water trans-
port across the apical plasma membrane of the renal
collecting ducts [1, 2]. AQP2 is regulated by short-
and long-term mechanisms. Short-time regulation implies
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AVP stimulated trafficking of AQP2 bearing intracellu-
lar vesicles to the apical plasma membrane of the collect-
ing ducts, thus increasing water permeability. When AVP
levels decline, the vesicles are retrieved by endocytosis.
Long-term regulation implies a rapid increase in AQP2
RNA expression, followed more slowly by an increase in
the intracellular protein levels. The long-term alteration
in concentrating capacity is presumed to be due to an
increase in total AQP2 caused by a change in gene tran-
scription [1]. AQP2 is excreted into the urine, and urinary
AQP2 (u-AQP2) can be used as a marker for the action
of AVP on the collecting ducts [1, 2].
In humans, 1 week of fasting is associated with a
marked increase in water excretion, suggesting impair-
ment in the urinary concentrating mechanism [3]. Animal
experiments have shown that rats fasted for 24 hours had
impaired urinary concentrating ability and that these rats
had down-regulated AQP2 [4]. The effect of 24 hours of
fasting in healthy humans on the urinary concentrating
ability is unknown, and the effect of fasting on u-AQP2
has not been studied in healthy humans.
If 24 hours of fasting impairs the urinary concentrating
ability, we expect that infusion of 3% saline decreases
urine volume and free water clearance (CH2O) to a lesser
degree than during nonfasting conditions. If a decrease
in urinary concentrating ability is due to down-regulation
of AQP2, we expect u-AQP2 to be lower after 24 hours
of fasting compared to nonfasting conditions.
We wanted to test the hypotheses that 24 hours of
fasting (1) changes the function of AQP2 forming renal
tubule cells, and (2) impairs the antidiuretic response to
hypertonic saline infusion compared to a control period.
METHODS
Subjects
The inclusion criteria were (1) age, 20 to 55 years
old; (2) both genders; and (3) body weight less than
100 kg. The exclusion criteria were (1) history or clini-
cal signs of disease of the heart, lungs, kidneys, or en-
docrine organs; (2) neoplastic disease; (3) arterial hyper-
tension; (4) alcohol or drug abuse; (5) medical treatment,
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except oral contraceptives; (6) unwillingness to partici-
pate; (7) abnormal laboratory screening tests (i.e., abnor-
mal blood hemoglobin, white cell count, platelets, plasma
sodium, plasma potassium, plasma creatinine, plasma al-
bumin, blood glucose, serum cholesterol, plasma bilirubin
and plasma alanine aminotransferase, or albuminuria or
glucosuria); (8) abnormal electrocardiogram (ECG); (9)
pregnancy; and (10) blood donation less than 1 month be-
fore the study. Withdrawal criterion was the development
of one or more of the exclusion criteria.
The local medical ethics committee approved the study
and written informed consent was obtained from all par-
ticipants.
Design
The crossover designed study consisted of a fasting
experiment and a control experiment each of 2 days’
duration with a time interval of 14 days between the
two experiments. In a 24-hour period immediately be-
fore each of the two experiments the subjects consumed
a standardized diet and drank 35 mL of tap water/kg body
weight. The fasting experiment was performed on 2 con-
secutive days. During the first day the subjects fasted for
24 hours and drank 35 mL of tap water/kg body weight.
During the second day the subjects were examined in the
laboratory. They received an oral water load of 200 mL/
30 minutes from 7:00 a.m. to 1:30 p.m., and saline 3%,
7 mL/kg body weight was infused intravenously from
11:00 a.m. to 11:30 a.m.
The control experiment was identical to the fasting ex-
periment except during the first day, where the subjects
consumed standardized food and water as the day be-
fore the experiments instead of fasting, and during the
second day where the subjects consumed a standardized
breakfast at 7:00 a.m.
Composition of diet and fluid intake
All subjects underwent a detailed interview to estab-
lish their usual physical activity during the whole day.
Energy requirement was calculated according to the for-
mula [100 kJ ∗ body weight (kg)] ∗ activity Factor (AF),
where the AF ranged from 1.3 to 2.0 depending on phys-
ical activity during work and spare time. AF of 1.3 in-
dicates no activity (i.e., staying in bed); AF of 1.4 to 1.5
indicates sedentary work and no physical activity during
spare time; AF of 1.6 to 1.7 indicates sedentary work with
some walking activity and some physical activity during
spare time; AF of 1.8 to 1.9 indicates standing all day; and
an AF of 2.0 indicates hard physical work and physical
activity during spare time. Subjects with energy require-
ment of 10,000 kJ and more received a food portion con-
taining 12,000 kJ; subjects with energy requirement less
than 10,000 received a food portion of 7500 kJ. The food
contained a specified amount of carbohydrates (55%),
protein (15%), and fat (30%), and the distribution and
amount were identical on all days (i.e., before the fast-
ing/control day, on the control day, and the breakfast on
the study day in the control experiment).
The subjects were not allowed to add any spices includ-
ing sodium to the food. All subjects accepted to eat all of
each food portion and were instructed to eat the food as it
was divided in three chief meals and three smaller meals
even distributed during the day. The subjects were asked
to keep their physical activity unchanged during the two
experiments. The subjects drank tap water 35 mL/kg each
24 hours during the study experiments, and nothing else.
Experimental procedure
During the first day a 24-hour urine collection was
performed and the subjects received lithium carbonate
300 mg at 10:00 p.m. for the measurements of lithium
clearance. During the second day the subjects arrived in
the laboratory at 7:30 a.m. The subjects were weighed be-
fore and after the experimental procedure. Smoking was
prohibited during the study. An intravenous catheter was
placed in each arm for collection of blood samples and in-
fusion of the tracer 51Cr-ethylenediaminetetraacetic acid
(EDTA). Urine was collected by voiding in the standing
or sitting position; otherwise the subjects were studied
in the supine position. Blood samples were drawn ev-
ery 30 minutes and analyzed for AVP, plasma creatinine,
plasma osmolality, plasma sodium, plasma potassium,
serum lithium, serum 51Cr-EDTA, and every 60 min-
utes for plasma renin concentration (PRC), angiotensin
II (Ang II), aldosterone, atrial and brain natriuretic pep-
tides (ANP and BNP, respectively). The total amount of
blood removed during the study was 350 mL of blood.
Immediately after each blood sample the volume drawn
was substituted by exactly the same volume of isotonic
saline to avoid any effect on the volume state of the sub-
jects in the fasting procedure as well as in the control
procedure. Urine was collected every 30 minutes and ana-
lyzed for u-AQP2, urinary osmolality, urinary cyclic AMP
(u-cAMP), urinary sodium, urinary potassium, urinary
creatinine, and urinary 51Cr-EDTA. Blood pressure and
heart rate were measured every 30 minutes throughout
the study. We divided the second day into eight clearance
periods (P1 to P8) of 30 minutes. P1 was from 9:30 a.m. to
10:00 a.m., P2 was from 10:00 a.m. to 10:30 a.m., P3 was
from 10:30 a.m. to 11:00 a.m., P4 was from 11:00 a.m. to
11:30 a.m., P5 was from 11:30 a.m. to 12:00 noon, P6 was
from 12:00 noon to 12:30 p.m., P7 was from 12:30 p.m. to
1:00 p.m., and P8 was from 1:00 p.m. to 1:30 p.m. Saline
3%, 7 mL/kg was infused during P4 from 11:00 a.m. to
11:30 a.m..
Measurements
We measured glomerular filtration rate (GFR) using
the renal clearance of 51Cr-EDTA employing the con-
stant infusion technique as previously described [5].
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AQP2 was measured by radioimmunoassay, as earlier
described [2]. Urine samples was centrifuged for 5 min-
utes at 1.6 ∗ 100g (3000 rpm) and 125 to 3000 lL of
the supernatant (depending on urinary osmolality) was
freeze dried and kept frozen at −20◦C until assayed. For
radioimmunoassay rabbit anti-AQP2 antibody was ob-
tained from Søren Nielsen (Department of Cell Biol-
ogy, Institute of Anatomy, Aarhus University, Aarhus,
Denmark). Minimal detection level was 32 pg/tube. The
coefficients of variation were 11.7% (interassay) and
5.9% (intra-assay).
AVP, Ang II, aldosterone, ANP, and BNP in plasma
were determined by radioimmunoassays after previous
extractions from plasma with C18 Sep-Pak (Water asso-
ciates, Milford, MA, USA) [5–8]. The antibody against
AVP was a gift from Professor Jacques Du¨rr (Miami,
FL, USA). Minimal detection level was 0.5 pmol/L. The
coefficients of variation were 13% (interassay) and 9%
(intra-assay). The antibody against Ang II was obtained
from the Department of Clinical Physiology, Glostrup
Hospital (Glostrup, Denmark). Minimal detection level
was 2 pmol/L plasma. The coefficients of variation were
12% (interassay) and 8% (intra-assay). Aldosterone in
plasma was measured by a modification [6] of the method
originally described [7] using a rabbit antialdosterone
antibody (Simoco, Denmark). Minimal detection level
was 42 pmol/L plasma. The coefficients of variation
were 13% (interassay) and 9% (intra-assay). Rabbit anti-
ANP antibody was obtained from the Department of
Clinical Chemistry, Bispebjerg Hospital (Copenhagen,
Denmark). Minimal detection level was 0.5 pmol/L
plasma. The coefficients of variation were 12% (interas-
say) and 10% (intra-assay). A rabbit anti-BNP antibody
without crossreactivity with a-ANP and urodilatin was
used. Minimal detection level was 0.5 pmol/L plasma. The
coefficients of variation were 11% (interassay) and 6%
(intra-assay).
PRC was measured by a commercial immunoradio-
metric assay (Nichols Institute Diagnostics, Geneva,
Switzerland). Minimal detection level was 1.4 lU/mL.
The coefficients of variation were 9.9% (interassay) and
2.5% (intra-assay).
u-cAMP was measured by radioimmunoassay as de-
scribed in the Instruction Manual Cyclic AMP EIA Kit
(catalogue number BT-730) (Biomedical Technologies
Inc., Stoughton, MA, USA). The BTI Cyclic AMP EIA
has been designed for the 96-well format. Specific an-
tibody and the enzyme-cAMP conjugate are combined
with standards or unknowns in the plates and incubated
18 to 24 hours at 4◦C. After washing the plate, en-
zyme activity is determined and unknowns calculated
from a standard curve prepared at the same time. Min-
imal detection level was 0.05 pmol/L urine. The co-
efficients of variation were 8% (interassay) and 3%
(intra-assay).
Plasma and urinary osmolality was measured by
freezing-point depression (advanced model 3900 multi-
sampling osmometer). CH2O was determined according
to the formula CH2O = V ÷ COsm, where V is urine vol-
ume, and COsm is the osmolality clearance.
Blood pressure was determined by UA-743 digital
blood pressure meter (A&D Company, Ltd., Tokyo,
Japan). Plasma and urinary concentrations of sodium and
potassium were measured by routine methods at the De-
partment of Clinical Biochemistry, Holstebro Hospital
(Holstebro, Denmark). All clearances were standardized
to a body surface area (BSA) of 1.73 m2.
Statistics
We used nonparametric tests to analyze data, due
to lack of normality. Results are presented as medians
with quartiles. Paired comparison was performed with
Wilcoxon’s signed rank test for two groups and with
Friedman’s test for more than two groups. Statistical level
of significance was at P = 0.05 in all analyses.
RESULTS
Demographics
We studied 14 healthy subjects, seven males and seven
females; median age was 25 years (24 to 25 years), height
178 cm (170 to 183 cm), weight 72.3 kg (63.3 to 81.6 kg),
body mass index (BMI) 22.8 (21.9 to 24.4) and blood pres-
sure 111 mm Hg systolic (106 to 116 mm Hg) and 66
mm Hg diastolic (63 to 68 mm Hg). Plasma sodium was
138 mmol/L (137 to 139 mmol/L), plasma potassium 4.0
mmol/L (3.8 to 4.2 mmol/L), plasma albumin 41 g/L (39
to 44 g/L), plasma creatinine 80 lmol/L (71 to 84 lmol/L),
serum osmolality 287 mOsm/kg (285 to 288 mOsm/kg),
and erythrocyte volume coefficient (EVF) 0.38 L (0.35 to
0.40 L).
Urinary effect variables during 24 hours of fasting
Table 1 shows that urine volume was 5% higher
(138 mL) than in the control experiment and u-cAMP was
19.8% lower (611 nmol/24 hours) after fasting compared
to the control procedure, but the differences were not sta-
tistically significant. u-AQP2, urinary osmolality, urinary
creatinine, urinary sodium, and urinary potassium were
all significantly reduced during fasting.
Effect variables after 24 hours of fasting
The effect variables are indicated in Table 2.In the fast-
ing experiment AVP was 27% higher than in the control
experiment (P < 0.013), whereas serum osmolality and
plasma sodium were significantly lower after fasting. We
did not observe hypoglycemia in any of the fasting sub-
jects (data not shown).
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Table 1. A fasting period of 24 hours and a control period of 24 hours in 14 healthy subjects corresponding to the first study day in the fasting
experiment respective control experiment
24 hours of fasting 24 hours with a standardized diet Significance
Urine volume mL/24 hours 2835 (2097–3003) 2697 (1961–3285) NS
Urinary aquaporin-2 lg/24 hours 1.41 (1.11–1.74) 1.68 (1.48–1.98) P < 0.013
Urinary osmolality mOsmol/kg/24 hours 265 (231–338) 366 (309–470) P < 0.002
Urinary creatinine mmol/24 hours 11 (10–13) 12 (11–16) P < 0.006
Urinary sodium mmol/24 hours 142 (113–172) 198 (173–241) P < 0.005
Urinary potassium mmol/24 hours 55 (39–63) 65 (56–82) P < 0.006
Urinary cyclic adenosine monophosphate nmol/24 hours 2472 (2381–3338) 3083 (2387–3624) NS
Medians with 25 and 75 percentiles.
Table 2. The effect of 24 hours of fasting compared to 24 hours with a standardized diet in 14 healthy subjects
24 hours of fasting 24 hours with a standardized diet Significance
Arginine vasopressin pmol/L 1.29 (1.06–1.48) 1.01 (0.90–1.11) P < 0.013
Serum osmolality mOsm/kg 284 (281–286) 288 (284–290) P < 0.024
Plasma sodium mmol/L 135 (133–136) 138 (137–139) P < 0.001
Plasma potassium mmol/L 4.1 (4.0–4.3) 4.1 (4.0–4.2) NS
Urinary aquaporin-2 ng/min 1.15 (1.02–1.32) 1.34 (1.24–1.56) P < 0.004
Urinary osmolality mOsmol/kg 103 (84–144) 138 (123–187) P < 0.005
Urine volume mL/min 7.27 (6.28–8.50) 7.47 (5.58–9.52) NS
Free water clearance mL/min 5.09 (3.66–6.04) 3.48 (3.10–5.84) NS
Urinary sodium mmol/min 0.165 (0.120–0.235) 0.230 (0.158–0.450) P < 0.003
Fractional excretion of sodium 0.011 (0.009–0.017) 0.022 (0.013–0.031) P < 0.005
Fractional excretion of lithium 0.227 (0.200–0.246) 0.267 (0.215–0.326) P < 0.008
Urinary cyclic adenosine monophosphate nmol/min 2.33 (2.01–2.82) 2.03 (1.72–2.82) NS
Mean arterial pressure mm Hg 80 (77–83) 82 (77–83) NS
Body weight kg 71.5 (62.3–80.9) 72.3 (63.3–81.6) P < 0.005
Plasma renin concentration lU/mL 11 (9–25) 12 (8–20) NS
Angiotensin II pmol/L 15 (11–23) 13 (8–20) NS
Aldosterone pg/L 155 (97–264) 80 (66–178) P < 0.005
Atrial natriuretic peptide pmol/L 3.5 (2.0–4.0) 4.6 (2.5–5.1) NS
Brain natriuretic peptide pmol/L 1.4 (1.0–2.4) 1.8 (1.3–3.8) NS
In the fasting experiment u-AQP2 was 14% lower (P <
0.004) and urinary osmolality was 25% lower than in the
control experiment (P < 0.005), whereas we did not find
any significant differences in urine volume and CH2O be-
tween the two experiments. In the fasting experiment
urinary sodium was 28% lower than after the control
experiment (P < 0.003), fractional excretion of sodium
(FENa) was 51% lower (P < 0.005) and fractional exrec-
tion of lithium (FELi) was 15% lower after fasting com-
pared to the control experiment (P < 0.008).
u-cAMP was not statistically different after fasting
compared to the control procedure. Blood pressure was
not affected by fasting, whereas body weight was slightly,
but significantly lower after fasting (P < 0.005).
We did not find any differences between the two exper-
iments in PRC or Ang II, but in the fasting experiment
aldosterone was 94% above the level in the control ex-
periment (P < 0.005). ANP and BNP were unchanged
after fasting.
Effect of 3% saline infusion on the effect variables after
24 hours of fasting
Figure 1A to J shows the effect of 3% saline infusion
on plasma AVP, serum osmolality, u-AQP2, urine volume,
CH2O, urinary osmolality, GFR, sodium excretion, FENa,
and FELi. Baseline of plasma results was defined as 10:30
a.m., and baseline of urine results was the urine collection
period from 10:00 a.m. to 10:30 a.m. (P2). Three percent
saline was infused from 11:00 a.m. to 11:30 a.m. (P4).
Figure 1A shows that the level of AVP was significantly
higher after fasting compared to the control period (P <
0.019) during the whole study period. In the fasting ex-
periment baseline was 1.3 pg/L (1.1 to 1.5 pg/L) vs. con-
trol 1.0 pg/L (0.9 to 1.1 pg/L) (P < 0.013). At the end
of the saline infusion AVP was 2.6 pg/L (1.9 to 3.1 pg/L)
vs. control 2.0 pg/L (1.8 to 2.5 pg/L) (P < 0.019). In each
experiment the increase was significant (P < 0.002), but
the relative increases were the same.
Figure 1B shows that serum osmolality was at a lower
level after fasting compared to the control period. The
difference was significant from baseline to 11/2 hours af-
ter the saline infusion (P < 0.034). In the fasting experi-
ment baseline was 284 mOsm/kg (281 to 286 mOsm/kg)
vs. control 288 mOsm/kg (284 to 290 mOsm/kg) (P <
0.024). At the end of the saline infusion serum osmo-
lality was 292 mOsm/kg (289 to 294 mOsm/kg) vs. con-
trol 296 mOsm/kg (293 to 298 mOsm/kg) (P < 0.002). In
each experiment, the increase was significant (P < 0.005),
but the relative increases were the same. In the fasting
procedure serum osmolality did not return to baseline as
serum osmolality did in the control procedure.
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Fig. 1. Results 14 healthy subjects with or without 24 hours of fasting. (A) Plasma vasopressin (AVP). (B) Serum osmolality. (C) Urinary excretion
of aquaporin-2 (u-AQP2). (D) Free water clearance (Cl-H2O). (E) Urine volume (F) Urine osmolality (u-osm). (G) Glomerular filtration rate
(GFR). (H) Urinary excretion of sodium (u-sodium). (I) Fractional excretion of sodium (FENa). (J) Fractional excretion of lithium (FELi). P1 is
the 30 minutes urinary collection from 09:30 a.m. to 10:00 a.m., P2 is from 10:00 a.m. to 10:30 a.m., P3 is from 10:30 a.m. to 11:00 a.m., P4 is from
11:00 a.m. to 11:30 a.m., P5 is from 11:30 a.m. to 12:00 noon, P6 is from 12:00 noon to 12:30 p.m., P7 is from 12:30 p.m. to 1:00 p.m., and P8 is from
1:00 p.m. to 1:30 p.m. 3% saline, 7 mL/kg was infused from 11:00 a.m. to 11:30 a.m. in each experiment. ∗P < 0.05 vs. control experiment.
Figure 1C shows that u-AQP2 was at a lower level af-
ter fasting compared to the control period. The difference
was significant from baseline to 1 hour after the saline in-
fusion (P < 0.022). In the fasting experiment baseline was
1.15 ng/min (1.02 to 1.32 ng/min) vs. control 1.34 ng/min
(1.24 to 1.56 ng/min) (P < 0.004). At the end of the saline
infusion, u-AQP2 was 1.23 ng/min (1.08 to 1.57 ng/min)
vs. control 1.61 ng/min (1.25 to 1.95 ng/min) (P < 0.022).
In each experiment the increase was not significant un-
til from baseline to 1 hour after the saline infusion (P <
0.013), but the relative increases were the same.
Figure 1D and E show that CH2O and urine volume
were not affected by fasting, apart from one hour after
the 3% saline infusion, where urine volume was lower af-
ter fasting. The difference was small, but significant (P <
0.047). In each experiment CH2O and urine volume de-
creased significantly after 3% saline infusion (P < 0.007),
but the relative decreases were the same.
Figure 1F shows that urinary osmolality was only
affected by fasting at baseline, where urinary os-
molality was significantly lower after fasting (P <
0.005). In each experiment urinary osmolality increased
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significantly from baseline to the end of the saline infusion
(P < 0.003).
Figure 1G shows that GFR was not affected by fasting.
In each experiment GFR decreased slightly, although sig-
nificantly from baseline to the end of the saline infusion
(P < 0.026). The relative decreases were not statistically
different.
Figure 1H and I show that urinary excretion of sodium
and FENa were significantly lower after fasting compared
to the control during the whole study period (0.023). In
each experiment urinary excretion of sodium and FENa
increased significantly (P < 0.007) after 3% sodium infu-
sion, but the relative increase did not differ significantly
between the two experiments.
Figure 1J shows that FELi was lower after fasting com-
pared to the control period during the whole study period,
but the difference was only statistically significant from
baseline to the end of the 3% saline infusion (P < 0.051).
In each experiment FELi increased significantly after 3%
saline infusion, but the relative increase did not differ
significantly between the two experiments.
u-cAMP was not significantly affected by fasting. In
the fasting procedure u-cAMP was 2.33 nmol/min (2.01
to 2.82 nmol/min) before, and increased 24% (P <
0.021) to 2.89 nmol/min (2.39 to 3.22 nmol/min) after
3% sodium infusion. In the control procedure u-cAMP
was 2.03 nmol/min (1.72 to 2.82 nmol/min) before, and
increased 47% (P < 0.041) to 2.98 nmol/min (2.14 to
4.65 nmol/min) after 3% sodium infusion. The relative
increases did not differ significantly between the two
procedures.
PRC, Ang II, aldosterone, ANP, and BNP
Table 3 shows the absolute values of PRC, Ang II, al-
dosterone, ANP, and BNP at 11:00 a.m., 12:00 noon, and
1:00 p.m.
The level of PRC did not differ between the two exper-
iments. In the fasting experiment before the 3% saline
infusion PRC was 11 lU (9 to 25 lU) vs. control 12 lU
(8 to 20 lU). At the end of the saline infusion PRC was
8 lU (7 to 17 lU) vs. control 9 lU (7 to 13 lU). In each
experiment the decrease was significant (P < 0.006), but
the relative increases were the same.
During the fasting experiment the level of Ang II
tended to be above the level in the control experiment,
but the difference was significant only at 12:00 noon (P <
0.05). In the fasting experiment before the 3% saline in-
fusion Ang II was 15 pmol/L (11 to 23 pmol/L) vs. control
13 pmol/L (8 to 20 pmol/L). At the end of the saline in-
fusion Ang II was 14 pmol/L (7 to 18 pmol/L) vs. control
8 pmol/L (6 to 14 pmol/L) (P < 0.05). In each experiment
the decrease was significant (P < 0.016), but the relative
increases were not statistically different.
During the fasting experiment aldosterone was at a
significantly higher level than in the control experiment
Table 3. Plasma renin concentration (PRC), angiotensin II,
aldosterone, atrial natriuretic peptide (ANP) and brain natriuretic
peptide (BNP) at 11:00 a.m., 12:00 noon, and 1:00 p.m. in the fasting
and control experiments (3% saline 7 mL/kg was infused from 11:00
to 11:30 a.m.)
11:00 a.m. 12:00 noon 1:00 p.m.
(before (30 minutes after (90 minutes after
infusion of infusion of infusion of
3% saline) 3% saline) 3% saline)
PRC lU/mL
Fasting 11 (9–25) 8 (7–17)a 8 (7–13)a
Control 12 (8–20) 9 (7–13)a 9 (7–12)a
Significance NS NS NS
Angiotensin II pmol/L
Fasting 15 (11–23) 14 (7–18)a 13 (9–17)a
Control 13 (8–20) 8 (6–14)a 9 (7–13)a
Significance NS P < 0.05 NS
Aldosterone pg/L
Fasting 155 (97–264) 104 (73–138)a 87 (67–117)a
Control 80 (66–178) 64 (55–108)a 60 (50–70)a
Significance P < 0.005 P < 0.008 P < 0.002
ANP pmol/L
Fasting 3.45 (1.95–3.95) 5.45 (4.18–6.73)a 4.15 (3.13–5.50)
Control 4.60 (2.48–5.13) 6.35 (4.10–8.10)a 4.55 (3.75–6.7)
Significance NS NS NS
BNP pmol/L
Fasting 1.35 (1.00–2.43) 1.55 (1.23–2.60)a 1.55 (1.23–2.25)a
Control 1.75 (1.28–3.78) 1.85 (1.45–4.25)a 1.95 (1.35–3.68)a
Significance NS NS NS
Results are expressed as medians with 25 and 75 percentiles.
aP < 0.05 vs.11:00 a.m.
(P < 0.008). In the fasting experiment before 3% saline
infusion aldosterone was 155 pg/L (97 to 264 pg/L) vs.
control 80 pg/L (66 to 178 pg/L) (P < 0.005) At the end
of the saline infusion aldosterone was 104 pg/L (73 to
138 pg/L) vs. control 64 pg/L (55 to 108 pg/L) (P < 0.008).
In each experiment the decrease was significant (P <
0.006), and during the fasting experiment aldosterone de-
creased significantly more than in the control experiment
(P < 0.048).
During the fasting experiment ANP and BNP did not
differ significantly from the control experiment. ANP and
BNP increased significantly after 3% saline infusion (P <
0.004) in each experiment. The increases were not statis-
tically different in the two experiments.
DISCUSSION
24 hours of fasting
In healthy subjects, 24 hours of fasting decreased uri-
nary excretion of AQP2. Vasopressin was increased de-
spite a reduction in serum osmolality and plasma sodium,
whereas CH2O, urine volume, and cAMP were not signif-
icantly changed.
Rats fasted for 24 hours developed a reduction in their
urinary concentrating capacity, since 24 hours of fasting
increased urine volume, suppressed AQP2 in the collect-
ing duct, and decreased u-osmolality, but CH2O and va-
sopressin were not measured [4]. In humans fasting for
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1 week, the urine volume increased [3]. The effect of fast-
ing on u-AQP2, CH2O, vasopressin, and urinary osmolal-
ity has never been investigated in humans before. Our
results are in accordance with the results from the study
of fasted rats [4] concerning u-AQP and urinary osmo-
lality, but we did not find any significant differences in
urine volume. However, in the present study the subjects
developed a slight degree of dehydration during the fast-
ing period. This was evident by the lower body weight,
lower urinary sodium excretion, lower FENa, and lower
plasma sodium after 24 hours of fasting compared to the
values after the 24 hours control period. The lower uri-
nary sodium excretion after fasting could be attributed
to the increase in plasma aldosterone, which most likely
was stimulated as a compensatory phenomenon to avoid
or reduce volume depletion. During this condition urine
volume would be expected to decrease. The fact that we
measured the same urine volume during fasting and dur-
ing the control period indicates that urine volume was
relatively increased during fasting. These findings com-
bined with a lower AQP2 excretion during fasting is in
good accordance with a reduced number of water chan-
nels in the collecting ducts due to a down-regulation of
AQP2 water channel formation, since vasopressin was
increased simultaneously. Why serum osmolality in the
fasting procedure did not return to baseline as serum os-
molality did in the control procedure is unclear. Possibly
steady state was not reached during the observation pe-
riod, which might indicate that after fasting the osmoreg-
ulatory system needs more time to reach steady state.
Rats fed a potassium free diet had decreased urinary
osmolality, increased urine volume, and down-regulation
of AQP2, and these changes preceded the onset of
hypokalemia [9]. The mechanism by which potassium
deprivation might decrease AQP2 expression was not
determined, but was suggested to be due to an inhibi-
tion of the translation process or an activation of the
AQP2 protein turnover [4]. We found urinary potassium
to be significantly lower after fasting compared to the
control period, but plasma potassium was unchanged. It
is unknown whether changes in potassium balance are
involved in the down regulation of the AQP2 channel
formation in the present study.
Fasting induced hypoglycemia in rats, but correction of
hypoglycemia did not alter the results in that study [4].
Fasting did not cause hypoglycemia in any of the subjects
in our study and thereby hypoglycemia is not of impor-
tance to our results.
The mechanisms of the down-regulation of u-AQP2
during fasting are not known. Vasopressin levels was in-
creased, whereas u-cAMP was not statistically increased
compared to the control procedure; actually u-cAMP
tended to be lower after fasting. This could indicate that
part of the explanation might be a decreased sensitivity
of the V2 receptors. Still, in the rat study [4], the down-
regulation of AQP2 expression did not occur in the inner
medulla despite the fact that vasopressin regulates AQP2
through V2 receptors in the entire collecting duct system.
If we assume that the same mechanisms are responsible
for the down-regulation of u-AQP2 in humans, a possi-
ble reduced sensitivity to vasopressin cannot be the only
explanation.
Fasting increases prostaglandin synthesis [4, 11]. In-
hibition of prostaglandin synthesis enhanced the antidi-
uretic activity of vasopressin and prostaglandins inhibit
the renal effect of vasopressin [12, 13]. Newer studies
in rats indicate that the prostaglandins act by retriev-
ing AQP2 that has been recruited to the plasma mem-
brane by vasopressin [14]. Studies of cell cultures of rat
kidney cells suggest that in some cases prostaglandins
exert their effect without the involvement of a cAMP-
dependent step [15]. We did not measure prostaglandins
in this study, and therefore we cannot tell if a possible in-
creased prostaglandin synthesis contributed to the down
regulation of u-AQP2.
Infusion of 3% saline
The acute antidiuretic response to 3% saline infusion
was not affected by 24 hours of fasting, but the decreased
urinary excretion of AQP2, the increased level of va-
sopressin, the decreased serum osmolality and plasma
sodium were maintained during infusion of 3% saline
compared to the control study.
The antidiuretic response to 3% saline after fasting has
never been investigated before. In agreement with the
results of the study of 3% saline infusion in healthy hu-
mans [2], we observed a significant increase in u-AQP2
and vasopressin after infusion of 3% saline, but the in-
crease was independent of whether or not the subjects
had fasted. ANP and BNP increased during infusion of
3% saline, which can be seen as compensation to pro-
mote sodium excretion, but the increases were not differ-
ent between the two experiments. Vasopressin secretion
is stimulated by increased tonicity sensed by hypotha-
lamic osmoreceptors, and by decreased plasma volume
sensed by volume receptors. Vasopressin binds to V2
receptors and induces increased water permeability in
the collecting duct by insertion of AQP2-bearing vesi-
cles in the apical plasma membrane [1, 2]. As mentioned,
plasma volume was slightly reduced during fasting. This
most likely stimulated vasopressin, since serum osmolal-
ity was decreased. However, the response to 3% saline
infusion was unaffected by a 24 hours period of fasting,
and the relative changes in AQP2, vasopressin, urine vol-
ume and CH2O were the same as during the control con-
ditions. This is surprising, and the mechanism is not clear
since formation of water channels in the collecting ducts
was down-regulated at the end of the fasting period. Part
of the explanation might be that the hypertonic saline is
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a very strong stimulus for formation of water channels
mediated via vasopressin as suggested by the significant
increase of u-cAMP in both groups. The increase of u-
cAMP was most pronounced in the control period, in-
dicating that the sensitivity to vasopressin was partly re-
duced, but still this possible reduced sensitivity could be
overridden by the strong stimulus of hypertonic saline.
Recent observations in a cell culture system of rat kid-
ney cells showed osmolality and solute composition to
be potent regulators of AQP2 protein synthesis [10]. In-
creased osmolality induced a higher level of AQP2. Ele-
vated osmolality induced by urea alone had no promoting
effect on AQP2 expression, whereas elevated osmolality
induced by sodium chloride promoted AQP2 expression
in a dose-dependent manner, suggesting sodium chloride
to be a key component in promoting AQP2 expression
[10]. The effect of cell media osmolality and solute com-
position on AQP2 expression seemed to be achieved via
another pathway than by cAMP, but the exact mechanism
was not determined. The increase in plasma osmolality
observed in our study was small compared to the marked
increase from 300 to 600 mOsm/kg. The small increase in
serum osmolality in our study is not likely to cause a dra-
matic increase in renal medullary osmolality. Whether a
direct effect of sodium is of importance for the formation
of water channels in the intact kidney is unknown for the
time being.
Studies in cultured renal epithelial cells from collecting
ducts have shown the presence of receptors for ANP, and
that ANP stimulate AQP2 trafficking of AQO2-bearing
vesicles to the apical plasma membrane via an increase in
cyclic guanosine monophosphate (cGMP) [16]. We found
a significant increase in ANP after hypertonic saline. This
increase in ANP could contribute to the increase of AQP2
excretion.
We conclude that (1) 24 hours of fasting decreased u-
AQP2 and reduced urine osmolality likely as a result of
decreased sensitivity of collecting duct cells to AVP, (2)
fasting-related insensitivity of collecting duct cells to AVP
was restored by saline infusion as indicated by increased
u-AQP2 and u-cAMP, and (3) in the setting of 3% saline
infusion, other factors such as the increased plasma ANP
levels could also contribute to the regulation of water
transport and u-AQP2 excretion.
ACKNOWLEDGMENTS
The study was supported by grants from Ringkøbing County. Lab-
oratory technicians Lisbeth Mikkelsen, Eva Mølgaard Jensen, Anne
Jaritz-Nielsen, Susan Milton Rasmussen, Henriette Hedelund Vorup Si-
monsen, and Anne Mette Ravn Torstensen, and Catering officer Hanne
Sahl and the staff at the Holstebro Hospital kitchen are thanked for
skillful technical assistance and commitment. The experiments comply
with the current laws of Denmark inclusive of ethics approval.
Reprints requests to Dr. Jørn Starklint, Department of Medicine and
Department of Medical Research, Holstebro Hospital, DK-7500 Holste-
bro, Denmark.
E-mail: ajos@ringamt.dk
REFERENCES
1. NIELSEN S, FROEKIAER J, MARPLES D, et al: Aquaporins in the kidney:
From molecules to medicine. Physiol Rev 82:205–244, 2002
2. PEDERSEN RS, BENTZEN H, BECH JN, PEDERSEN EB: Effect of water
deprivation and hypertonic saline infusion on urinary AQP2 excre-
tion in healthy humans. Am J Physiol Renal Physiol 280:F860–F867,
2001
3. SIGLER MH: The mechanism of the natriuresis of fasting. J Clin
Invest 55:377–387, 1975
4. AMLAL H, CHEN Q, HABO K, et al: Fasting down regulates renal water
channel AQP2 and causes polyuria. Am J Physiol Renal Physiol
280:F513–F523, 2001
5. PEDERSEN EB, DANIELSEN H, SPENCER ES: Effect of indapamide
on renal plasma flow, glomerular filtration rate and arginine vaso-
pressin in plasma in essential hypertension. Eur J Clin Pharmacol
26:543–547, 1984
6. PEDERSEN EB, EISKJæR H, MADSEN B, et al: Effect of captopril on
renal extraction of renin, angiotensin II, atrial natriuretic peptide
and vasopressin, and renal vein renin ratio in patients with arte-
rial hypertension and unilateral renal artery disease. Nephrol Dial
Transplant 8:1064–1070, 1993
7. RASK-MADSEN J, BRUUNSGAARD A, MUNCK O, et al: The significance
of bile acids and aldosterone for the electrical hyper polarization
of human rectum in obese patients treated with intestinal bypass
operation. Scand J Gastroenterol 9:417–426, 1974
8. JENSEN KT, CARSTENS J, IVARSEN P, PEDERSEN EB: A new, fast and
reliable radio immunoassay of brain natriuretic peptide in human
plasma. Reference values in healthy subjects and in patients with
different diseases. Scand J Clin Lab Invest. 57:529–540, 1997
9. AMLAL H, KRANE CM, CHEN Q, SOLEIMANI M: Early polyuria and
urinary concentrating defect in potassium deprivation. Am J Physiol
Renal Physiol 279:F655–F663, 2000
10. STORM R, KLUSSMANN E, GEELHAAR A, et al: Osmolality and so-
lute composition are strong regulators of AQP2 expression in renal
principal cells. Am J Physiol Renal Physiol 284:F189–F198, 2003
11. KERNDT PR, NAUGHTON JL, DRISCOLL CE, LOXTERKAMP DA: Fasting:
The history, patophysiology and complications. West J Med 137:379–
399, 1982
12. FEJES-TOTH G, MAGYAR A, WALTER J: Renal response to vasopressin
after inhibition of prostaglandin synthesis. Am J Physiol 232:F416–
F423, 1977
13. PEDERSEN RS, BENTZEN H, BECH JN, PEDERSEN EB: Effect of an
acute oral ibuprofen intake on urinary aquaporin-2 excretion in
healthy humans. Scand J Clin Lab Invest 61:631–640, 2001
14. ZELENINA M, CHRISTENSEN BM, PALME´R J, et al: Prostaglandin E2
interaction with AVP: Effects on AQP2 phosphorylation and distri-
bution. Am J Physiol Renal Physiol 278:F388–F394, 2000
15. TAMMA G, WIESNER B, FURKERT J, et al: The prostaglandin E2
analogue sulprostone antagonizes vasopressin-induced antidiuresis
through activation of Rho. J Cell Science 116:3285–3294, 2003
16. BOULEY R, BRETON S, SUN T, et al: Nitric oxide and atrial natri-
uretic factor stimulate cGMP-dependent membrane insertion of
aquaporin 2 in renal epithelial cells. J Clin Invest 106:1115–1126,
2000
